CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

Core Viewpoint - China Medical System Holdings Limited (CMS) has entered into a Distribution Agreement with Novartis for the exclusive rights to import, distribute, sell, and promote Ranibizumab Injection (Lucentis) and Brolucizumab Injection (Beovu) in mainland China for five years [1]. Group 1: Product Information - Lucentis is the first anti-VEGF drug approved for ophthalmic use in China, treating multiple ocular neovascular diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [2][4]. - Beovu, a next-generation anti-VEGF drug, was approved in May 2025 for DME treatment, offering advantages such as a smaller molecular weight and improved retinal anatomical structure [2][7]. - The Chinese market for anti-VEGF drugs is projected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion by 2030, with the number of patients with ocular neovascular diseases expected to rise from 47.8 million in 2019 to 61.2 million in 2030 [5]. Group 2: Company Strategy and Market Position - CMS Vision, a subsidiary of CMS, aims to become a leading ophthalmology pharmaceutical company in China by developing innovative ophthalmic pharmaceuticals and medical devices [3]. - The collaboration with Novartis is expected to enhance CMS Vision's competitiveness in ophthalmology, creating synergies with existing products and improving overall team efficiency [3]. - CMS has established strong commercialization capabilities and extensive networks in specialty therapeutic fields, including ophthalmology, which supports its growth strategy in emerging markets [12].